Etravirine resistance associated mutations in HIV-infected patients failing efavirenz or nevirapine in the Spanish antiretroviral resistance database

AIDS. 2010 Jan 28;24(3):469-71. doi: 10.1097/QAD.0b013e328331a4b8.

Abstract

The prevalence of etravirine resistance mutations was examined in genotypes derived from 1343 HIV-infected patients failing nevirapine or efavirenz in the resistance database of the Spanish AIDS Research Network (ResRIS). Overall, etravirine-resistant genotypes were recognized in 18.7% of patients, with no significant differences between failures under nevirapine or efavirenz. Thus, more than 80% patients with prior failure to nonnucleoside reverse transcriptase inhibitors could potentially benefit from etravirine rescue therapy.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Alkynes
  • Anti-HIV Agents / therapeutic use
  • Benzoxazines / therapeutic use
  • Cyclopropanes
  • Drug Resistance, Viral / genetics*
  • HIV-1 / genetics*
  • Humans
  • Mutation / genetics*
  • Nevirapine / therapeutic use
  • Nitriles
  • Pyridazines / therapeutic use*
  • Pyrimidines
  • Reverse Transcriptase Inhibitors / therapeutic use*
  • Spain
  • Treatment Failure

Substances

  • Alkynes
  • Anti-HIV Agents
  • Benzoxazines
  • Cyclopropanes
  • Nitriles
  • Pyridazines
  • Pyrimidines
  • Reverse Transcriptase Inhibitors
  • etravirine
  • Nevirapine
  • efavirenz